Get the Stockscreener App
4.60
1.50%
-0.07
Olema Pharmaceuticals Inc stock is traded at $4.60, with a volume of 468.47K.
It is down -1.50% in the last 24 hours and up +46.03% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$4.67
Open:
$4.7
24h Volume:
468.47K
Relative Volume:
0.51
Market Cap:
$384.19M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.1395
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-18.15%
1M Performance:
+46.03%
6M Performance:
-62.90%
1Y Performance:
-53.25%
1-Day Range:
$4.51
$4.80
1-Week Range:
$4.3512
$5.69
52-Week Range:
$2.86
$16.62
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
4.60 | 384.19M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by BVF Inc. IL - MarketBeat
Olema Oncology to Participate in Upcoming Investor Conferences | OLMA Stock News - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday - MarketBeat
Deep Track Capital LP Sells 557,167 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Barclays PLC - Defense World
Boxer Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Market Insight: Olema Pharmaceuticals Inc (OLMA)’s Notable Drop, Closing at 4.60 - DWinneX
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Renaissance Technologies LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News - GuruFocus
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Breast Cancer Drug Developer Olema Awards 104,400 Stock Options to Key New Hires - Stock Titan
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Legal & General Group Plc - Defense World
A look into Olema Pharmaceuticals Inc (OLMA)’s deeper side - Sete News
Renaissance Technologies LLC Has $917,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight - GlobeNewswire Inc.
Can you now get a good deal on Olema Pharmaceuticals Inc’s shares? - uspostnews.com
HC Wainwright Reaffirms “Buy” Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - The AM Reporter
Walleye Capital LLC Invests $391,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Financial Snapshot: Analyzing Olema Pharmaceuticals Inc (OLMA)’s Key Ratio Metrics - DWinneX
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by JPMorgan Chase & Co. - Defense World
Olema Pharmaceuticals’ (OLMA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Market Recap Check: Olema Pharmaceuticals Inc (OLMA)’s Negative Finish at 3.76, Up/Down -8.52 - DWinneX
Silverarc Capital Management LLC Reduces Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Avoro Capital Advisors LLC Takes $9.63 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Geode Capital Management LLC Decreases Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models - marketscreener.com
Olema Oncology Announces New Preclinical Data for OP-3136 - GlobeNewswire
Cancer Breakthrough: New Drug OP-3136 Achieves 28-Day Tumor Regression in Multiple Cancer Types - Stock Titan
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update - MarketBeat
Financial Analysis: Olema Pharmaceuticals Inc (OLMA)’s Ratios Unveil Key Insights - DWinneX
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet - Yahoo Finance
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
Alliancebernstein L.P. Has $1.83 Million Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Vanguard Group Inc. Has $15.65 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Bain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals Inc (OLMA) Stock: From Low to High in 52 Weeks - investchronicle.com
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):